TRIM21 and interstitial lung disease: Following disease remission, she received a combination of MMF and MTX as maintenance therapy, considering the poor prognosis suggested by the coexistence of anti-Ro52 and anti-MDA5 antibody, and severe complications with RP-ILD and PNM.